Use of anti HHV-6 transfer factor for the treatment of two patients with chronic fatigue syndrome (CFS). Two case reports.
Specific Human Herpes virus-6 (HHV-6) transfer factor (TF) preparation, administered to two chronic fatigue syndrome patients, inhibited the HHV-6 infection. Prior to treatment, both patients exhibited an activated HHV-6 infection. TF treatment significantly improved the clinical manifestations of CFS in one patient who resumed normal duties within weeks, whereas no clinical improvement was observed in the second patient. It is concluded that HHV-6 specific TF may be of significant value in controlling HHV-6 infection and related illnesses.
Ablashi
D V
DV
Advanced Biotechnologies Inc., Columbia, MD 21046, USA.
Levine
P H
PH
De Vinci
C
C
Whitman
J E
JE
Pizza
G
G
Viza
D
D
D000284:Administration, Oral; D000328:Adult; D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D015673:Fatigue Syndrome, Chronic / Q000276:immunology / Q000628:therapy* / Q000821:virology; D005260:Female; D006566:Herpesviridae Infections / Q000628:therapy*; D015654:Herpesvirus 6, Human / Q000276:immunology*; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D012680:Sensitivity and Specificity; D014165:Transfer Factor / Q000627:therapeutic use*
D000998:Antiviral Agents; D014165:Transfer Factor